Hims & Hers Bets on Longevity While the Evidence Catches Up

Paul Jackson

November 18, 2026

Key Points

  • Hims’ new Peptides+ platform pairs five compounded treatments with ongoing care and lab testing, expanding its push into longevity

 

  • Monthly revenue per average subscriber rose 30% to $105 in Q3, showing the importance of selling more services through its platform

 

  • Easier compounding access does not establish effectiveness, leaving clinical evidence and customer trust central to the business case

A bigger relationship with the same customer

The business appeal of longevity is easy to see. A customer’s interest in feeling healthier does not end when one prescription runs out.

Hims & Hers (NYSE: HIMS) is moving further into that relationship with Wednesday’s launch of Peptides+, offering compounded sermorelin, glutathione, NAD+, vitamin B12 and L-carnitine to eligible patients.

The brand name covers more than peptides: NAD+ is a coenzyme, while B12 is a vitamin. What connects the offerings is the broader market for energy, recovery and healthy aging.

That market brings a difficult question into the consultation: how much benefit can these particular treatments reliably deliver?

Peptides+ could deepen Hims’ customer relationships, but lasting revenue will depend on earning trust in a category where important clinical questions remain unresolved.

The financial attraction goes beyond another prescription

Hims already has a substantial audience.

Its third-quarter revenue reached $890.4 million, up 49%, while subscribers increased 13% to nearly 2.8 million. Monthly revenue per average subscriber rose 30% to $105, from $81 a year earlier.

Those figures predate Peptides+. They nevertheless help explain the strategy: growth can come from expanding the relationship with an existing customer, alongside attracting someone new.

The Care+ offering includes twice-yearly lab testing, ongoing check-ins and access to provider messaging. That creates repeated contact with the platform, potentially supporting additional services and retention.

More contact also means more work to deliver the service.

Hims’ Q3 gross margin fell to 57% from 74%. That does not establish the economics of this new specialty, but it makes profitability an important part of the expansion story. Adding revenue and improving returns are separate achievements.

Longevity is becoming a public-market business story. The next developments will concern which platforms turn attention into repeat business—and at what cost.

From Health Trend to Public Company—Follow the Business in Your Inbox

The regulatory opening has boundaries

The distinction between access and approval is essential here.

Compounded drugs are not FDA-approved. The agency does not review their safety, effectiveness or quality before marketing, even though compounding can serve legitimate medical needs.

The recent federal policy change is narrower than a general green light for longevity treatments.

HHS’ conditional enforcement-discretion policy covers six specified peptides, including BPC-157 and TB-500, which Hims plans to add later. Those six are separate from the five initial Peptides+ offerings.

The policy imposes conditions and can be revisited if safety or product-quality concerns arise. It does not approve the resulting drugs.

For Hims, that leaves future product expansion dependent on an evolving regulatory framework.

Biological promise still needs clinical results

The evidence gap is particularly clear with NAD+.

A 2026 systematic review covering 113 studies found no eligible clinical-outcome trials evaluating intravenous or intramuscular NAD+ itself for anti-aging or wellness. The review covered research through October 2025.

That finding does not prove the treatment cannot work. It means those outcomes had not been established by eligible trials in the review.

It also cannot be applied indiscriminately to every compound, formulation or medical use in Hims’ lineup.

This is where personalized care meets a limitation that convenience cannot solve. Lab measurements and patient check-ins can inform care; they do not replace controlled trials establishing a treatment’s benefits and risks.

The launch starts the commercial test

Hims has a distribution platform and an established subscriber base. Peptides+ gives it another way to bring customers into ongoing care.

The harder task begins after enrollment: delivering a service people continue to value while documenting outcomes, identifying safety problems and managing the cost of support.

The next quarterly disclosures can begin to show uptake and any effect on spending per subscriber or margins, if Hims provides that detail. Stronger clinical evidence will require its own studies and timetable.

A successful launch can establish demand. Keeping that demand is the longer test.

Explore More Stories in Health

Back to WallStAccess Homepage


Disclaimer

Wall Street Access is an independent financial publisher. Wall Street Access is not a financial advisor. No company mentioned has compensated Wall Street Access for the preparation, publication or distribution of this article. This content is provided for informational and educational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Investing involves risk, including the possible loss of principal.

Prices, market capitalizations, financial figures and other market data are based on information available as of the date and time of publication and may change without notice. Information is drawn from public sources believed to be reliable but is not guaranteed to be complete or accurate. Opinions and expectations expressed are our own and may change as new information becomes available.

Readers should conduct their own due diligence and contact a licensed financial professional before making any investment decision. Past performance does not guarantee future results. Any material ownership interest or conflict of interest, where applicable, will be disclosed separately.

Subscribe to Wall Street Access

Author

Paul Jackson

RELATED ARTICLES